351 related articles for article (PubMed ID: 32504377)
1. Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache.
Scott LJ
Drugs; 2020 Jun; 80(9):893-904. PubMed ID: 32504377
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
3. Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.
Detke HC; Millen BA; Zhang Q; Samaan K; Ailani J; Dodick DW; Aurora SK
Headache; 2020 Feb; 60(2):348-359. PubMed ID: 31710104
[TBL] [Abstract][Full Text] [Related]
4. Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials.
Yang Y; Wang Z; Gao B; Xuan H; Zhu Y; Chen Z; Wang Z
J Headache Pain; 2020 Feb; 21(1):14. PubMed ID: 32046655
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
6. Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache.
Ossipov MH; Raffa RB; Pergolizzi JV
Drugs Today (Barc); 2020 Jan; 56(1):5-19. PubMed ID: 32055802
[TBL] [Abstract][Full Text] [Related]
7. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment.
Dodick DW; Goadsby PJ; Lucas C; Jensen R; Bardos JN; Martinez JM; Zhou C; Aurora SK; Yang JY; Conley RR; Oakes T
Cephalalgia; 2020 Aug; 40(9):935-948. PubMed ID: 32050782
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
9. CGRP pathway monoclonal antibodies for cluster headache.
Chan C; Goadsby PJ
Expert Opin Biol Ther; 2020 Aug; 20(8):947-953. PubMed ID: 32241175
[TBL] [Abstract][Full Text] [Related]
10. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
Ament M; Day K; Stauffer VL; Skljarevski V; Rettiganti M; Pearlman E; Aurora SK
J Headache Pain; 2021 Feb; 22(1):6. PubMed ID: 33549036
[TBL] [Abstract][Full Text] [Related]
11. [Galcanezumab for episodic and chronic cluster headache].
Pohl H; Holle-Lee D; Broicher SD; Schwerdtner I; Gantenbein AR; Gaul C
Schmerz; 2023 Jun; 37(3):168-174. PubMed ID: 35476143
[TBL] [Abstract][Full Text] [Related]
12. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
[TBL] [Abstract][Full Text] [Related]
13. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.
Khan S; Olesen A; Ashina M
Cephalalgia; 2019 Mar; 39(3):374-389. PubMed ID: 29110503
[TBL] [Abstract][Full Text] [Related]
14. Galcanezumab: First Global Approval.
Lamb YN
Drugs; 2018 Nov; 78(16):1769-1775. PubMed ID: 30378008
[TBL] [Abstract][Full Text] [Related]
15. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.
Förderreuther S; Zhang Q; Stauffer VL; Aurora SK; Láinez MJA
J Headache Pain; 2018 Dec; 19(1):121. PubMed ID: 30594122
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.
Ruff DD; Ford JH; Tockhorn-Heidenreich A; Stauffer VL; Govindan S; Aurora SK; Terwindt GM; Goadsby PJ
Eur J Neurol; 2020 Apr; 27(4):609-618. PubMed ID: 31692188
[TBL] [Abstract][Full Text] [Related]
17. Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies.
Ailani J; Pearlman E; Zhang Q; Nagy AJ; Schuh K; Aurora SK
Eur J Neurol; 2020 Mar; 27(3):542-549. PubMed ID: 31595600
[TBL] [Abstract][Full Text] [Related]
18. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
[TBL] [Abstract][Full Text] [Related]
19. Drug profile: galcanezumab for prevention of cluster headache.
Mudugal D; Monteith TS
Expert Rev Neurother; 2021 Feb; 21(2):145-155. PubMed ID: 33206562
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]